Denosumab, an antibody against RANKL that mimics the physiological role of OPG, is currently in clinical use for osteoporosis and for the treatment of skeletal related events in patients with bone metastasis resulting from solid tumours. Here, TNFRSF11B is linked to osteoporosis.